GH Research PLC filings document foreign private issuer current reports for a clinical-stage biopharmaceutical company developing mebufotenin product candidates for depression. The company’s Form 6-K reports furnish press releases, corporate presentations, manuscripts, and conference materials related to GH001 in treatment-resistant depression, including Phase 2b results, open-label extension data, and FDA/IND regulatory updates.
The filing record also covers operating and financial results, material-event disclosures, shareholder voting matters, capital-structure information, material agreements, and clinical or regulatory disclosures. These documents describe the company’s research and development focus, product-candidate pipeline, governance reporting, and formal exhibits used to communicate trial publications and business updates.
GH Research PLC’s common stock is reported as beneficially owned by FMR LLC, which reported 6,482,945 shares, or 9.4%, with sole voting and dispositive power over those shares. Abigail P. Johnson is also listed with beneficial ownership of the same 6,482,945 shares, reporting no voting power and sole dispositive power over them. The report says one or more other persons may receive dividends or sale proceeds from the shares, but no individual person’s interest exceeds 5% of the outstanding common stock.
GH Research PLC (GHRS) will present data from its GH001-TRD-201 and GH001-BD-202 clinical trials at the 39th European College of Neuropsychopharmacology (ECNP) annual meeting, scheduled for October 10–13, 2026, in Munich, Germany. Three posters are scheduled for Poster Session 2 on October 11, 2026, with presentations by Prof. Wiesław J. Cubała, Prof. Bernhard T. Baune, and Dr. Max de Leeuw. The company will sponsor an industry satellite symposium on October 10 titled “Achieving remission in treatment-resistant depression: current evidence and research on rapid-acting antidepressants.”
GH Research PLC (GHRS) reports that it will hold one-on-one investor meetings during the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14–16, 2026, in New York. The company discloses this as a report of a foreign private issuer on Form 6-K.
GH Research PLC (GHRS) reported that director Florian Schonharting2,303 share options$0.025 per Ordinary Share, are immediately fully vested, but are not exercisable until September 8, 2028, and expire on September 8, 2033. Following this award, he holds 2,303 share options directly.
RA Capital Management, L.P., together with affiliated funds and managers Peter Kolchinsky and Rajeev Shah, reports beneficial ownership of 4,897,182 ordinary shares of GH Research PLC, representing 7.1% of the outstanding class, based on 68,642,287 ordinary shares outstanding as of the issuer’s Form 6-K filed August 6, 2026.
The holdings include 4,768,564 shares held by RA Capital Healthcare Fund, L.P. and 128,618 shares held by RA Capital Nexus Fund II, L.P., for which RA Capital has voting and dispositive power under advisory arrangements. The reporting persons and funds include detailed disclaimers of beneficial ownership and group status for purposes other than Section 13(d).
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of GH Research PLC ordinary shares. Through Lynx1 Master Fund LP and a managed account, they collectively report 13,263,288 Ordinary Shares, representing 19.3% of the class, with shared voting and dispositive power and no sole power. The ownership percentage is based on 68,608,919 Ordinary Shares outstanding as of May 12, 2026, as reported by the company. The Lynx1 Fund has the right to receive dividends and sale proceeds from the reported shares.
GH Research PLC director Duncan Moore received a compensatory grant of 2,202 share options on 2026-08-11. The options carry an exercise price of 0.0250 per ordinary share and expire on 2033-08-11. They are immediately fully vested but are not exercisable until August 11, 2028.
GH Research PLC director Dermot John Hanley received a grant of share options covering 2,202 underlying ordinary shares on August 11, 2026. The options have an exercise price of $0.025 per share, are immediately fully vested, but are not exercisable until August 11, 2028, and expire on August 11, 2033. Following this grant, Hanley holds 2,202 share options directly.
GH Research PLC director Michael Forer reported two grants of share options over Ordinary Shares. One grant covers 2,202 options at an exercise price of $0.0250 per share, which are immediately fully vested but not exercisable until August 11, 2028 and expire on August 11, 2033. A second grant covers 100,000 options at the same exercise price, expiring August 11, 2033, with 25% vesting and becoming exercisable on August 11, 2027 and the remaining 75% vesting in equal monthly installments over three years thereafter.
GH Research PLC reported second quarter 2026 results, with a loss of $15.1 million for the quarter and $34.1 million for the six months ended June 30, 2026, compared with $9.3 million and $20.1 million in the prior-year periods. Operating expenses rose as research and development reached $12.4 million in the quarter (vs. $9.0 million) and general and administrative expenses $7.1 million (vs. $5.7 million), mainly from higher clinical and professional costs.
Liquidity strengthened: cash, cash equivalents and marketable securities totaled $362.7 million at June 30, 2026, up from $280.7 million at year-end 2025, driven by an April underwritten offering of 6,527,779 ordinary shares at $18.00 per share, yielding estimated net proceeds of $111.2 million. Net cash used in operating activities was $25.7 million for the first half. The company established a $200.0 million at-the-market program, with no sales to date, and states it has sufficient resources for at least twelve months.
Clinically, GH Research is preparing a global pivotal Phase 3 program of its inhaled mebufotenin candidate GH001 in treatment-resistant depression, after completing key Phase 1 studies and receiving FDA written feedback that its CMC and device plans appear Phase 3 ready. Intellectual property was reinforced with a new U.S. patent on aerosol mebufotenin methods expected to expire no earlier than 2043 and maintenance of a European patent on mebufotenin uses through at least 2040, alongside multiple publications and presentations of GH001 data.